Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN

Evaluation médico-économique de la Stimulation unilatérale du Sinus Carotidien Dans le Traitement de l'Hypertension artérielle résistante: Essai Multicentrique contrôlé, randomisé, Ouvert Avec évaluation d'efficacité Tensionnelle et de sécurité

Medico-economics assessment (cost-effectiveness) of the unilateral carotid barostimulation with Barostim NeoTM compared to usual care in patients with resistant hypertension (multicenter randomized, PROBE trial), followed-up for 12 months, with a lifetime-long modeling.

Main inclusion Criteria:

• 18-85 years old men or women
• Resistant hypertension on 4 medications incl. thiazide or thiazide-like diuretics at appropriate doses + spironolactone (unless spironolactone intolerance)
• Essential hypertension documented (bilan < 2 years old)
• eGFR ≥ 30 ml/min/1,73 m2
• No carotid condition associated with a contra-indication for Barostim NeoTM use

Main exclusion Criteria:

• Patients with documented secondary hypertension, besides Obstructive Sleep Apnea
• Symptomatic orthostatic hypotension
• Patient with prior syncope or myocardial infarction, unstable angina pectoris, or cerebrovascular within 3 months before inclusion
• Patient with type 1 diabetes mellitus
• Patient with permanent atrial fibrillation
• Patient with brachial circumference of ≥ 46cm
• Patient with BMI>45kg/m2
• Pregnancy, breastfeeding or planning a pregnancy within 2 years
• NeoTM implantation anatomic contra-indications